The 36-month beta value for VRNA is at 0.43. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRNA is 62.79M, and currently, shorts hold a 14.09% of that float. The average trading volume for VRNA on October 09, 2024 was 1.19M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VRNA) stock’s latest price update
Verona Pharma Plc ADR (NASDAQ: VRNA) has seen a decline in its stock price by -0.87 in relation to its previous close of 32.05. However, the company has experienced a 9.59% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-30 that Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024.
VRNA’s Market Performance
VRNA’s stock has risen by 9.59% in the past week, with a monthly rise of 15.57% and a quarterly rise of 77.19%. The volatility ratio for the week is 5.37% while the volatility levels for the last 30 days are 4.90% for Verona Pharma Plc ADR The simple moving average for the past 20 days is 6.80% for VRNA’s stock, with a 65.11% simple moving average for the past 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with Wells Fargo repeating the rating for VRNA by listing it as a “Overweight.” The predicted price for VRNA in the upcoming period, according to Wells Fargo is $50 based on the research report published on October 03, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $38, previously predicting the price at $35. The rating they have provided for VRNA stocks is “Buy” according to the report published on May 22nd, 2023.
Wedbush gave a rating of “Outperform” to VRNA, setting the target price at $27 in the report published on September 19th of the previous year.
VRNA Trading at 17.10% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.38% of loss for the given period.
Volatility was left at 4.90%, however, over the last 30 days, the volatility rate increased by 5.37%, as shares surge +13.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +40.51% upper at present.
During the last 5 trading sessions, VRNA rose by +9.59%, which changed the moving average for the period of 200-days by +91.62% in comparison to the 20-day moving average, which settled at $29.75. In addition, Verona Pharma Plc ADR saw 59.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from ZACCARDELLI DAVID, who sale 600,000 shares at the price of $3.76 back on Sep 11 ’24. After this action, ZACCARDELLI DAVID now owns 15,250,704 shares of Verona Pharma Plc ADR, valued at $2,254,320 using the latest closing price.
Hahn Mark W, the Chief Financial Officer of Verona Pharma Plc ADR, sale 600,000 shares at $3.76 during a trade that took place back on Sep 11 ’24, which means that Hahn Mark W is holding 14,339,688 shares at $2,254,080 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -137.94 for the present operating margin
- 0.05 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -133.65. The total capital return value is set at -0.34. Equity return is now at value -56.89, with -34.02 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at -0.25. The debt to equity ratio resting at 1.29. The interest coverage ratio of the stock is -36.32.
Currently, EBITDA for the company is -67.15 million with net debt to EBITDA at 1.44. When we switch over and look at the enterprise to sales, we see a ratio of 2542.3. The receivables turnover for the company is 0.26for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.61.
Conclusion
In conclusion, Verona Pharma Plc ADR (VRNA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
